MSBase oral and poster presentations for ECTRIMS 2017
Ilya Kister, New York University School of Medicine, United States - poster presentation:
Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis
Johannes Lorscheider, University Hospital of Basel, Switzerland - poster presentation:
Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis
Tomas Kalincik, University of Melbourne and Royal Melbourne Hospital, Australia
Poster presentations:
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study.
Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years.
Risk of secondary progressive multiple sclerosis: a longitudinal study. (Adam Fambiatos - MD student, University of Melbourne).
Contribution of inflammation to disability accrual in primary progressive multiple sclerosis. (Jordana Hughes - MD student, University of Melbourne).
Oral Presentation:
Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. (Bernd Merkel - University of Melbourne Postdoctoral Research Fellow)
William Brown, MSBase Research Fellow, Melbourne, Australia - oral presentation:
The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis
Yara Fragoso, Metropolitan University of Santos, Brazil - ePoster Presentation:
Halting disability progression in multiple sclerosis with immunomodulatory injectable treatments: is it achievable?
Tim Spelman, MSBase Statistician - poster presentations:
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from the MSBase Registry in preparation for a cost effectiveness model: Patients switching within firstline agents or to Natalizumab or Fingolimod in active RRMS
Persistence to fingolimod compared with other disease modifying therapies in the Australian Real-World setting using the MSBase Registry
Vilija Jokubaitis, University of Melbourne, Australia - poster presentation:
Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis
Amy Kunchok, University of Melbourne, Australia - poster presentation:
Prognostic value of low level MRI activity in treated RRMS
Myintzu Min, John Hunter Hospital, Newcastle, Australia - poster presentation:
Silent lesions on MRI - shifting goal post for treatment decisions in MS
Back